Ophthalmic formulations containing tyrosine kinase inhibitors, such as Nintedanib, Axitinib, Sorafenib, and Pazopanib are described. The ophthalmic formulations can contain microparticles or nanoparticles of the tyrosine kinase inhibitor. Also described are methods of using the ophthalmic formulations for treating ocular surface diseases, such pterygium, including recurrent pterygium, and hyperemia associated with pterygium.本發明揭露一種眼用調配物，其含有例如尼達尼布、阿西替尼、索拉非尼及帕唑帕尼之酪胺酸激酶抑制劑，該眼用調配物可含有酪胺酸激酶抑制劑之微米粒子或奈米粒子，本發明更揭露一種使用眼用調配物於治療眼表疾病(如翼狀贅肉，包括復發性翼狀贅肉及與翼狀贅肉相關聯的充血)的方法。
